GILD pipeline diversification targets long-acting HIV, cell therapies, ADCs
GILD says pipeline diversification has expanded across virology, oncology and inflammation, with multiple new launches and clinical milestones expected, including long-acting HIV therapies, differentiated cell therapies and advanced ADC technologies.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.